生物制药公司"结构疗法"(Structure Therapeutics Inc,股票代码GPCR)当日盘中大幅下跌5.24%,引发了市场关注。公司主要从事新型口服慢性疾病药物的研发,但业务前景不佳或许是股价下跌的主因。
该公司核心产品GSBR-1290用于治疗2型糖尿病和肥胖症,但距离上市尚有一段距离。同时针对肺部和心血管疾病的其他在研产品进展缓慢,短期内难有新药上市推动营收增长。
财务状况也是压力之一。最新财报显示,结构疗法去年净亏损高达3426万美元,每股亏损0.6美元。而营收则为零,表明公司暂无实际产品获利。现金流状况或将进一步恶化,如不能适时融资可能引发资金链断裂风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.